

THE R&D COST OF A NEW MEDICINE

JORGE MESTRE-FERRANDIZ,
JON SUSSEX AND ADRIAN TOWSE

DECEMBER 2012



Office of Health Economics
Southside
7th Floor
105 Victoria Street
London SW1E 6QT
United Kingdom
www.ohe.org

©2012
All rights reserved
Printed in the United Kingdom
ISBN 978-1-899040-19-3

This publication has undergone a rigorous peer review by the independent OHE Editorial Board and other experts in the field. The views expressed are those of the authors and do not necessarily represent those of the OHE.

ABOUT THE AUTHORS

Dr Jorge Mestre-Ferrandiz is Director of Consulting at the Office of Health Economics. His research interests include pharmaceutical pricing and reimbursement systems worldwide, the economics of the pharmaceutical industry, the economics of innovation and incentives for encouraging medical R&D.

Jon Sussex is Deputy Director at the Office of Health Economics. His areas of expertise include health care expenditure; efficiency, competition and incentives in health care systems; the role of the private sector in publicly funded health care; and the economic regulation of the pharmaceutical industry.

Prof Adrian Towse is Director of the Office of Health Economics. His current research includes the use of “risk-sharing” arrangements between health care payers and pharmaceutical companies, including value-based pricing approaches; the economics of pharmacogenetics for health care payers and the pharmaceutical industry; economic issues that affect both R&D for and access to treatments for diseases prevalent in the developing world; the economics of medical negligence; and measuring productivity in health care.

ACKNOWLEDGEMENTS

This work was partially funded by an unrestricted research grant from AstraZeneca. We also would like to thank CMRI for allowing us to access their data. We are grateful to Prof Pedro-Pita Barros, Universidade Nova de Lisboa; Prof Martin Buxton, Brunel University; Prof Patricia Danzon, University of Pennsylvania; and Dr Nancy Mattison, The Mattison Group, for comments on an earlier draft.

List of Illustrations and Tables	iii
Executive Summary	v
Introduction and Context	1
Context: Setting the Scene	2
The Cost of a New Medicine—the Mean	6
Policy Discussions around the Cost Estimates	16
Factors Affecting Development Costs	18
Out-of-Pocket Costs	18
Success Rates	19
Development Times	24
Cost of Capital	25
Sensitivity Analysis: Impact of Changing the Key Variables	28
A New Estimate for Drug Development Costs: Our Analysis	30
Data and Methods	34
Results	37
Comparing Our Analysis with the Published Analyses	39
Sensitivity Analysis	40
Therapeutic Areas	42
Success Rates	42
Development Times	47
Overall R&D Costs	50
Compound Origin: Self-Originated versus Licensed-In	53
Firm Size	56
Biologics and Biopharmaceuticals	58
Drivers of Trends in R&D Costs	61
Drivers of Out-of-Pocket Costs	62
Drivers of Failure Rates	65
Drivers of Development Times	67
A New Drug Development Paradigm?	68
Summary and Conclusions	71
Annex 1. List of Papers Providing Quantitative Evidence	73
Annex 2. Sensitivity Analysis	74
Glossary	79
References	81

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.